Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
AGMB compared with OCS: revenue, margins and what each company keeps, and the suppliers and customers both name
AGMB
Agomab Therapeutics NV
Change
Mkt cap
Revenue
Revenue
OCS
Oculis Holding AG
Change
Mkt cap
Revenue
Revenue
vs
Compare
AGMB
Agomab Therapeutics NV
vs
OCS
Oculis Holding AG
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
AGMB: latest quarter not drawable. OCS: latest quarter not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
AGMB, solid
OCS, dashed
AGMB
Agomab Therapeutics NV
Change
7.14
▼
−10.14%
· post 7.15
Mkt cap
$255.9M
OCS
Oculis Holding AG
Change
8.28
▲
+0.52%
· post 8.28
Closed
Oct 30 '26
Mkt cap
$496.3M
vs
Compare
Closed
Oct 30 '26
AGMB
Agomab Therapeutics NV
vs
OCS
Oculis Holding AG
7.14
▼
−10.14%
post 7.15
Price
8.28
▲
+0.52%
post 8.28
$255.9M
Mkt cap
$496.3M
Change
Change
AGMB
7.14
▼
−10.14%
vs
OCS
8.28
▲
+0.52%
Closed
Oct 30 '26
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
No disclosed counterparties: AGMB, OCS.
Role chip = supplier or customer
Source: SEC EDGAR